Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NMTC vs TCMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: NMTC 1 – 5 TCMD Matrix Metrics: NMTC 2 – 8 TCMD

As of Nov 20, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas TCMD carries 40.1/100 (SELL) at $25.60 (17.4x Forward P/E, 9.4% operating margin).

  • Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. TCMD 40.1/100 SELL), TCMD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -63.4% operating margin) and revenue trajectory (+7.1% vs. +16.3% YoY).
  • Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMTC vs TCMD
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$25.60
-1.5% 1D
Market Cap $582.2M
TTM Revenue $356M
Forward P/E 17.4x
Beta / 30D Vol 0.95β · 52% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 37.0 Fund 44.0 Flow 65.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 54
RSI-14: 53.6 · SMA20: $25.49 · SMA50: $23.76

6-Pillar Scorecard Institutional Category Breakdown (NMTC 1 – 5 TCMD)

Columns: Metric · NMTC · TCMD
1. Valuation Multiples TCMD
Forward P/E N/M 17.4x
Trailing P/E N/M 25.2x
PEG Ratio N/M 17.79x
EV / Revenue 0.3x 1.5x
2. Growth & Scale NMTC
Revenue Growth (YoY) +16.3% +7.1%
Earnings Growth (YoY) +0.0% -13.9%
TTM Revenue (USD) $12M $356M
Market Cap $6.1M $582.2M
3. Profitability & Quality TCMD
Gross Margin 23.0% 77.0%
Operating Margin -63.4% 9.4%
Net Profit Margin -59.7% 6.7%
Return on Equity (ROE) -124.7% 11.0%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) -$7.6M $29M
Cash Flow Margin -60.7% 8.1%
Net Cash / Leverage $2.6M Net Cash $58M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 54.9% (15th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity N/A 67.6% of Rev ($241M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMTC (2) vs TCMD (8)
Institutional Metric NMTC TCMD Criterion Row Edge
Market Capitalization
Scale
$6.1M $582.2M Larger Scale TCMD
Trailing P/E Ratio
Valuation
N/M 25.2x Lower Multiple TCMD
Forward P/E Ratio
Valuation
N/M 17.4x Lower Multiple TCMD
Revenue Growth (YoY)
Growth
+16.3% +7.1% Higher Growth NMTC
Operating Margin (TTM)
Profitability
-63.4% 9.4% Higher Margin TCMD
Net Profit Margin
Profitability
-59.7% 6.7% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
-124.7% 11.0% Higher ROE TCMD
52-Week Range Position
Momentum
2% ($1–$5) 29% ($21–$38) Stronger Trend TCMD
Beta / 30D Volatility
Risk Regime
1.55β · 105% Vol 0.95β · 52% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 40.1 / 100 (SELL) Higher Composite NMTC
Trailing 12M Revenue (USD)
Operating Scale
$12M $356M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.0% 77.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev 17.79x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($2.6M Net Cash) $29M ($58M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +42.21 pp
NMTC: -33.46% · TCMD: +8.75%
3M Horizon TCMD +79.12 pp
NMTC: -69.53% · TCMD: +9.59%
6M Horizon TCMD +85.14 pp
NMTC: -82.33% · TCMD: +2.81%
1Y Horizon TCMD +2.16 pp
NMTC: +3.49% · TCMD: +5.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NMTC Revenue TCMD Revenue NMTC Op. Margin TCMD Op. Margin Margin Leader
FY2018 N/A $140M N/A 2.1% TCMD
FY2019 N/A $190M N/A 5.5% TCMD
FY2020 N/A $190M N/A -1.9% TCMD
FY2021 $0M $210M -5735.9% -0.8% TCMD
FY2022 $0M $250M -5860.2% -5.2% TCMD
FY2023 $0M $270M -612.3% 6.6% TCMD
FY2024 $0M $290M -344.3% 7.6% TCMD
FY2025 $10M $330M -46.5% 8.9% TCMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TCMD CONSOLIDATION
98d in phase · OBV DISTRIBUTION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $582.2M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published

Investor FAQ NMTC vs TCMD Key Questions & Quantitative Answers

As of Nov 20, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NMTC carries a Unified Composite Score of 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin), whereas TCMD carries 40.1/100 (SELL) at $25.60 (17.4x Forward P/E, 9.4% operating margin). Composite vs. Pillar Nuance: While NMTC currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. TCMD 40.1/100 SELL), TCMD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -63.4% operating margin) and revenue trajectory (+7.1% vs. +16.3% YoY). Technical & Structure Timing Caution: NMTC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMTC leads the Growth & Scale pillar: NMTC posts +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin), compared with TCMD at +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NMTC cumulative revenue shifted N/A while TCMD shifted +135.7%. In operating R&D and SG&A reinvestment, NMTC deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($241M) (0 disclosures) for TCMD.

TCMD screens cheaper on headline valuation multiples. NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin), whereas TCMD trades at 17.4x Forward P/E, 25.2x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMTC (-124.7% ROE) versus TCMD (11.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk). By comparison, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.95β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.